Rosiglitazone Reduces Inflammation in Diabetic Patients with Heart Disease
Author Information
Author(s): Wang Guang, Zhang Zhe, Yu Jie, Zhang Fuchun, He Liyun, Wei Jinru, Mao Jieming, Wang Xian
Primary Institution: Peking University Third Hospital
Hypothesis
Does rosiglitazone treatment lower levels of soluble adhesion molecules and inflammation markers in type 2 diabetic patients with coronary artery disease after PCI?
Conclusion
Rosiglitazone reduces chronic inflammation and improves endothelial dysfunction markers in diabetic patients with coronary artery disease.
Supporting Evidence
- Rosiglitazone treatment significantly decreased plasma levels of sICAM-1.
- Plasma CRP levels were significantly reduced after 6 months of treatment.
- Hemoglobin A1c levels decreased significantly in the rosiglitazone group.
- Fasting plasma insulin and glucose levels were significantly lower after treatment.
- Weight gain was observed but not significantly different from baseline.
- Plasma levels of sP-selectin did not change significantly with treatment.
- Patients in the rosiglitazone group had fewer coronary events compared to controls.
Takeaway
This study shows that a diabetes medication called rosiglitazone can help lower inflammation in people with heart problems.
Methodology
116 diabetic patients with CAD were randomized to receive rosiglitazone or not for 6 months, and plasma levels of adhesion molecules were measured.
Potential Biases
Potential bias due to the open-label design and patient selection.
Limitations
The study did not assess long-term effects beyond 6 months.
Participant Demographics
Patients aged 45 to 79 years, diagnosed with CAD and type 2 diabetes.
Statistical Information
P-Value
p<0.001
Confidence Interval
370.4 (332.4–421.9) pg/mL versus 423.5 (327.4–500.3) pg/mL
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website